Drug Trial Radar · NCT01924793
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Last checked: Nov 19, 2026Latest source record: Jul 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Aug 2013
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Ansun Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
Conditions
- Parainfluenza
Interventions
DAS181-F02 Dry Powder in BulkDrug
Administered via DPI
DAS181-F02 Nebulized Formulation Inhaled DoseDrug
Administered via Nebulizer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability.Time frame: 2 years
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Children's Hospital of Orange County
Orange, California
Stanford University Medical Center
Palo Alto, California
University of Chicago
Chicago, Illinois
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
University of Kansas Cancer Center
Kansas City, Kansas
John Hopkins University School of Medicine
Baltimore, Maryland
Brigham & Women's Hospital
Boston, Massachusetts
University of Minnesota, School of Medicine
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York
Weill Cornell Medical College-Peds
New York, New York
Duke University
Durham, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
St. Jude Children's Research Hospital
Memphis, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Fred Hutchinson Cencer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.